Anju, Clinical Trials Information Network Win Best of Show at SCOPE Europe 2025
By Clinical Research News Staff
October 16, 2025 | The SCOPE Europe 2025 Best of Show winners have been announced! This year, 22 finalists presented their products in the exhibit hall, and attendees voted for the most innovative and impactful technologies, tools, products, and solutions used by life sciences.
The winners are Anju Software and Clinical Trials Information Network, who was named Rookie of the Year. Company descriptions of their products are listed below.
Anju Software | Luminee V1.0 | Booth 48
https://www.anjusoftware.com/eclinical/luminee/
Luminee is a persona-based ecosystem of interconnected virtual assistants powered by specialized AI agents that support automating tedious tasks to accelerate trial timelines and reduce costs. Luminee's initial focus is reducing trial database build times and effort by 90%.
Clinical Trials Information Network | Clinical Trials Easily Understood | Booth 44
https://clinicaltrials.eu
ClinicalTrials.eu is a patient-centric, multilingual search platform connecting patients with research sites across borders. It provides daily updated data from verified clinical trial registries and presents it in clear, localized, and understandable form for patients and their families. What makes it unique is its ability to link patients and clinical centers internationally, overcoming language and geographic barriers that have long limited access to clinical research in Europe. The platform supports cross-border trial discovery, particularly valuable for patients with rare diseases, who often must travel abroad to find suitable studies. The new release introduces four additional language versions: Danish, Dutch, Romanian, and Austrian German, expanding the existing network that already includes English, German, French, Spanish, Polish, and Italian. ClinicalTrials.eu operates on a fully automated content generation system, enabling continuous creation and synchronization of trial data across all local domains.
Leave a comment

